Is there clinical value in measuring suPAR levels in FSGS?

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 8, 2013, Pages 1273-1275

  Sever, Sanja ^a   Trachtman, Howard ^b   Wei, Changli ^c   Reiser, Jochen ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; UROKINASE;

CLINICAL TRIAL (TOPIC); DISEASE COURSE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GLOMERULOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; KIDNEY TUMOR; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PROTEINURIA;

FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84881243062     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06170613     Document Type: Editorial

References (13)

1. D'Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398-2411, 2011
2. Bock ME, Price HE, Gallon L, Langman CB: Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: A single-center report. Clin J Am Soc Nephrol 8: 1304-1311, 2013
3. Sharma M, Sharma R, McCarthy ET, Savin VJ: "The FSGS factor:" Enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 10: 552-561, 1999
4. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115-2121, 2010
5. Montuori N, Ragno P: Multiple activities of a multifaceted receptor: Roles of cleaved and soluble uPAR. Front Biosci 14: 2494-2503, 2009
6. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang QY, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960, 2011
7. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J: Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55-63, 2008
8. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J; PodoNet and FSGS CT Study Consortia: Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23: 2051-2059, 2012
9. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH: Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int: 2013
10. Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H: Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates [published online ahead of print June 3, 2013]. Transplantation doi:10.1097/TP.0b013e3182977ab1
11. Thunø M, Macho B, Eugen-Olsen J: suPAR: Themolecular crystal ball. Dis Markers 27: 157-172, 2009
12. Riisbro R, Christensen IJ, Høgdall C, Brünner N, Høgdall E: Soluble urokinase plasminogen activator receptor measurements: Influence of sample handling. Int J Biol Markers 16: 233-239, 2001
13. Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher- Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM: Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome [published online ahead of print June 5, 2013]. Kidney Int doi: 10.1038/ki.2013.211